ID   5NTC_HUMAN              Reviewed;         561 AA.
AC   P49902; B7Z382; D3DR91; Q5JUV5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   22-JUL-2015, entry version 145.
DE   RecName: Full=Cytosolic purine 5'-nucleotidase;
DE            EC=3.1.3.5;
DE   AltName: Full=Cytosolic 5'-nucleotidase II;
GN   Name=NT5C2; Synonyms=NT5B, NT5CP, PNT5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=7999131; DOI=10.1006/bbrc.1994.2752;
RA   Oka J., Matsumoto A., Hosokawa Y., Inoue S.;
RT   "Molecular cloning of human cytosolic purine 5'-nucleotidase.";
RL   Biochem. Biophys. Res. Commun. 205:917-922(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-3.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-502, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   INVOLVEMENT IN SPG45.
RX   PubMed=24482476; DOI=10.1126/science.1247363;
RA   Novarino G., Fenstermaker A.G., Zaki M.S., Hofree M., Silhavy J.L.,
RA   Heiberg A.D., Abdellateef M., Rosti B., Scott E., Mansour L.,
RA   Masri A., Kayserili H., Al-Aama J.Y., Abdel-Salam G.M., Karminejad A.,
RA   Kara M., Kara B., Bozorgmehri B., Ben-Omran T., Mojahedi F.,
RA   Mahmoud I.G., Bouslam N., Bouhouche A., Benomar A., Hanein S.,
RA   Raymond L., Forlani S., Mascaro M., Selim L., Shehata N.,
RA   Al-Allawi N., Bindu P.S., Azam M., Gunel M., Caglayan A., Bilguvar K.,
RA   Tolun A., Issa M.Y., Schroth J., Spencer E.G., Rosti R.O., Akizu N.,
RA   Vaux K.K., Johansen A., Koh A.A., Megahed H., Durr A., Brice A.,
RA   Stevanin G., Gabriel S.B., Ideker T., Gleeson J.G.;
RT   "Exome sequencing links corticospinal motor neuron disease to common
RT   neurodegenerative disorders.";
RL   Science 343:506-511(2014).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 1-536 IN COMPLEX WITH
RP   ALLOSTERIC EFFECTOR AND MAGNESIUM IONS, AND SUBUNIT.
RX   PubMed=17405878; DOI=10.1074/jbc.M700917200;
RA   Wallden K., Stenmark P., Nyman T., Flodin S., Graeslund S.,
RA   Loppnau P., Bianchi V., Nordlund P.;
RT   "Crystal structure of human cytosolic 5'-nucleotidase II: insights
RT   into allosteric regulation and substrate recognition.";
RL   J. Biol. Chem. 282:17828-17836(2007).
CC   -!- FUNCTION: May have a critical role in the maintenance of a
CC       constant composition of intracellular purine/pyrimidine
CC       nucleotides in cooperation with other nucleotidases.
CC       Preferentially hydrolyzes inosine 5'-monophosphate (IMP) and other
CC       purine nucleotides.
CC   -!- CATALYTIC ACTIVITY: A 5'-ribonucleotide + H(2)O = a ribonucleoside
CC       + phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Note=Binds 1 Mg(2+) ion per subunit.;
CC   -!- ENZYME REGULATION: Allosterically activated by various compounds,
CC       including ATP.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:17405878}.
CC   -!- INTERACTION:
CC       P48047:ATP5O; NbExp=3; IntAct=EBI-742084, EBI-355815;
CC       P51116:FXR2; NbExp=3; IntAct=EBI-742084, EBI-740459;
CC       Q7L9L4:MOB1B; NbExp=3; IntAct=EBI-742084, EBI-2558745;
CC       Q86TA1:MOB3B; NbExp=3; IntAct=EBI-742084, EBI-751703;
CC       Q70IA8:MOB3C; NbExp=3; IntAct=EBI-742084, EBI-9679267;
CC       Q9Y5B8:NME7; NbExp=4; IntAct=EBI-742084, EBI-744782;
CC       Q6ZVK8:NUDT18; NbExp=3; IntAct=EBI-742084, EBI-740486;
CC       O00560:SDCBP; NbExp=3; IntAct=EBI-742084, EBI-727004;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P49902-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49902-2; Sequence=VSP_054235;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Spastic paraplegia 45, autosomal recessive (SPG45)
CC       [MIM:613162]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness
CC       and spasticity of the lower limbs. Rate of progression and the
CC       severity of symptoms are quite variable. Initial symptoms may
CC       include difficulty with balance, weakness and stiffness in the
CC       legs, muscle spasms, and dragging the toes when walking. In some
CC       forms of the disorder, bladder symptoms (such as incontinence) may
CC       appear, or the weakness and stiffness may spread to other parts of
CC       the body. Some SPG45 patients manifest mental retardation,
CC       contractures and learning disability.
CC       {ECO:0000269|PubMed:24482476}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the 5'(3')-deoxyribonucleotidase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D38524; BAA07529.1; -; mRNA.
DR   EMBL; AK295593; BAH12118.1; -; mRNA.
DR   EMBL; AL139817; CAI40080.1; -; Genomic_DNA.
DR   EMBL; AL360001; CAI40080.1; JOINED; Genomic_DNA.
DR   EMBL; AL360001; CAI13473.1; -; Genomic_DNA.
DR   EMBL; AL139817; CAI13473.1; JOINED; Genomic_DNA.
DR   EMBL; CH471066; EAW49656.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49657.1; -; Genomic_DNA.
DR   EMBL; BC001595; AAH01595.1; -; mRNA.
DR   CCDS; CCDS7544.1; -. [P49902-1]
DR   PIR; JC2436; JC2436.
DR   RefSeq; NP_001127845.1; NM_001134373.2. [P49902-1]
DR   RefSeq; NP_036361.1; NM_012229.4. [P49902-1]
DR   RefSeq; XP_005269693.1; XM_005269636.3. [P49902-1]
DR   RefSeq; XP_005269696.1; XM_005269639.3. [P49902-2]
DR   UniGene; Hs.97439; -.
DR   PDB; 2J2C; X-ray; 2.20 A; A=1-536.
DR   PDB; 2JC9; X-ray; 1.50 A; A=1-536.
DR   PDB; 2JCM; X-ray; 2.15 A; A=1-536.
DR   PDB; 2XCV; X-ray; 2.30 A; A=1-536.
DR   PDB; 2XCW; X-ray; 1.90 A; A=1-536.
DR   PDB; 2XCX; X-ray; 2.30 A; A=1-536.
DR   PDB; 2XJB; X-ray; 2.30 A; A=1-536.
DR   PDB; 2XJC; X-ray; 2.00 A; A=1-536.
DR   PDB; 2XJD; X-ray; 2.00 A; A=1-536.
DR   PDB; 2XJE; X-ray; 2.30 A; A=1-536.
DR   PDB; 2XJF; X-ray; 2.10 A; A=1-536.
DR   PDB; 4H4B; X-ray; 2.90 A; A=1-536.
DR   PDBsum; 2J2C; -.
DR   PDBsum; 2JC9; -.
DR   PDBsum; 2JCM; -.
DR   PDBsum; 2XCV; -.
DR   PDBsum; 2XCW; -.
DR   PDBsum; 2XCX; -.
DR   PDBsum; 2XJB; -.
DR   PDBsum; 2XJC; -.
DR   PDBsum; 2XJD; -.
DR   PDBsum; 2XJE; -.
DR   PDBsum; 2XJF; -.
DR   PDBsum; 4H4B; -.
DR   ProteinModelPortal; P49902; -.
DR   SMR; P49902; 3-488.
DR   BioGrid; 116627; 24.
DR   IntAct; P49902; 11.
DR   MINT; MINT-1436872; -.
DR   STRING; 9606.ENSP00000339479; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB00811; Ribavirin.
DR   DEPOD; P49902; -.
DR   PhosphoSite; P49902; -.
DR   BioMuta; NT5C2; -.
DR   DMDM; 1703012; -.
DR   MaxQB; P49902; -.
DR   PaxDb; P49902; -.
DR   PeptideAtlas; P49902; -.
DR   PRIDE; P49902; -.
DR   DNASU; 22978; -.
DR   Ensembl; ENST00000343289; ENSP00000339479; ENSG00000076685.
DR   Ensembl; ENST00000404739; ENSP00000383960; ENSG00000076685.
DR   GeneID; 22978; -.
DR   KEGG; hsa:22978; -.
DR   UCSC; uc001kwo.3; human. [P49902-1]
DR   UCSC; uc010qqp.2; human.
DR   CTD; 22978; -.
DR   GeneCards; GC10M104837; -.
DR   HGNC; HGNC:8022; NT5C2.
DR   HPA; HPA003751; -.
DR   MIM; 600417; gene.
DR   MIM; 613162; phenotype.
DR   neXtProt; NX_P49902; -.
DR   Orphanet; 320396; Autosomal recessive spastic paraplegia type 45.
DR   PharmGKB; PA31801; -.
DR   eggNOG; NOG75103; -.
DR   GeneTree; ENSGT00550000074539; -.
DR   HOGENOM; HOG000246075; -.
DR   HOVERGEN; HBG000025; -.
DR   KO; K01081; -.
DR   OMA; AMLMPHE; -.
DR   OrthoDB; EOG7QK0BX; -.
DR   PhylomeDB; P49902; -.
DR   TreeFam; TF315266; -.
DR   BioCyc; MetaCyc:HS01216-MONOMER; -.
DR   BRENDA; 3.1.3.5; 2681.
DR   Reactome; REACT_121388; Abacavir metabolism.
DR   Reactome; REACT_2086; Purine catabolism.
DR   SABIO-RK; P49902; -.
DR   ChiTaRS; NT5C2; human.
DR   EvolutionaryTrace; P49902; -.
DR   GenomeRNAi; 22978; -.
DR   NextBio; 35479172; -.
DR   PRO; PR:P49902; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; P49902; -.
DR   CleanEx; HS_NT5C2; -.
DR   ExpressionAtlas; P49902; baseline and differential.
DR   Genevisible; P49902; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0008253; F:5'-nucleotidase activity; EXP:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0050146; F:nucleoside phosphotransferase activity; TAS:Reactome.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0046085; P:adenosine metabolic process; IBA:GO_Central.
DR   GO; GO:0017144; P:drug metabolic process; TAS:Reactome.
DR   GO; GO:0046040; P:IMP metabolic process; IBA:GO_Central.
DR   GO; GO:0055086; P:nucleobase-containing small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0016310; P:phosphorylation; TAS:GOC.
DR   GO; GO:0006144; P:purine nucleobase metabolic process; TAS:Reactome.
DR   GO; GO:0006195; P:purine nucleotide catabolic process; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.50.1000; -; 3.
DR   InterPro; IPR023214; HAD-like_dom.
DR   InterPro; IPR008380; HAD-SF_hydro_IG_5-nucl.
DR   InterPro; IPR016695; Pur_nucleotidase.
DR   PANTHER; PTHR12103; PTHR12103; 1.
DR   Pfam; PF05761; 5_nucleotid; 1.
DR   PIRSF; PIRSF017434; Purine_5'-nucleotidase; 1.
DR   SUPFAM; SSF56784; SSF56784; 1.
DR   TIGRFAMs; TIGR02244; HAD-IG-Ncltidse; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Alternative splicing;
KW   Complete proteome; Cytoplasm; Hereditary spastic paraplegia;
KW   Hydrolase; Magnesium; Metal-binding; Neurodegeneration;
KW   Nucleotide metabolism; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome.
FT   CHAIN         1    561       Cytosolic purine 5'-nucleotidase.
FT                                /FTId=PRO_0000064389.
FT   REGION      202    210       Substrate binding. {ECO:0000255}.
FT   COMPBIAS    549    561       Asp/Glu-rich (acidic).
FT   ACT_SITE     52     52       Nucleophile.
FT   ACT_SITE     54     54       Proton donor.
FT   METAL        52     52       Magnesium.
FT   METAL        54     54       Magnesium; via carbonyl oxygen.
FT   METAL       351    351       Magnesium.
FT   BINDING     127    127       Allosteric activator 1.
FT   BINDING     154    154       Allosteric activator 2.
FT   BINDING     354    354       Allosteric activator 2.
FT   BINDING     436    436       Allosteric activator 1; via carbonyl
FT                                oxygen.
FT   BINDING     453    453       Allosteric activator 2.
FT   MOD_RES     502    502       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   VAR_SEQ       1     34       MSTSWSDRLQNAADMPANMDKHALKKYRREAYHR -> MSK
FT                                EG (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054235.
FT   VARIANT       3      3       T -> A (in dbSNP:rs10883841).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_024244.
FT   VARIANT     136    136       Q -> R (in dbSNP:rs12262171).
FT                                /FTId=VAR_030242.
FT   HELIX         5     13       {ECO:0000244|PDB:2JC9}.
FT   HELIX        21     28       {ECO:0000244|PDB:2JC9}.
FT   HELIX        31     33       {ECO:0000244|PDB:2JC9}.
FT   STRAND       36     39       {ECO:0000244|PDB:2JC9}.
FT   HELIX        43     45       {ECO:0000244|PDB:2JC9}.
FT   STRAND       48     51       {ECO:0000244|PDB:2JC9}.
FT   TURN         55     57       {ECO:0000244|PDB:2JC9}.
FT   STRAND       58     60       {ECO:0000244|PDB:4H4B}.
FT   HELIX        64     79       {ECO:0000244|PDB:2JC9}.
FT   HELIX        84     88       {ECO:0000244|PDB:2JC9}.
FT   STRAND      101    103       {ECO:0000244|PDB:2JC9}.
FT   TURN        104    107       {ECO:0000244|PDB:2JC9}.
FT   STRAND      108    112       {ECO:0000244|PDB:2JC9}.
FT   STRAND      117    123       {ECO:0000244|PDB:2JC9}.
FT   STRAND      126    128       {ECO:0000244|PDB:2XCV}.
FT   HELIX       130    136       {ECO:0000244|PDB:2JC9}.
FT   TURN        147    149       {ECO:0000244|PDB:2JC9}.
FT   STRAND      150    152       {ECO:0000244|PDB:2JC9}.
FT   HELIX       156    158       {ECO:0000244|PDB:2JC9}.
FT   HELIX       159    174       {ECO:0000244|PDB:2JC9}.
FT   STRAND      178    181       {ECO:0000244|PDB:2JC9}.
FT   STRAND      184    187       {ECO:0000244|PDB:2JC9}.
FT   STRAND      190    193       {ECO:0000244|PDB:2JC9}.
FT   HELIX       194    210       {ECO:0000244|PDB:2JC9}.
FT   HELIX       214    220       {ECO:0000244|PDB:2JC9}.
FT   HELIX       222    225       {ECO:0000244|PDB:2JC9}.
FT   HELIX       231    242       {ECO:0000244|PDB:2JC9}.
FT   STRAND      243    248       {ECO:0000244|PDB:2JC9}.
FT   HELIX       253    263       {ECO:0000244|PDB:2JC9}.
FT   STRAND      266    271       {ECO:0000244|PDB:2JC9}.
FT   HELIX       279    282       {ECO:0000244|PDB:2JC9}.
FT   STRAND      284    289       {ECO:0000244|PDB:2JC9}.
FT   HELIX       294    296       {ECO:0000244|PDB:2JC9}.
FT   STRAND      302    306       {ECO:0000244|PDB:2JC9}.
FT   TURN        307    310       {ECO:0000244|PDB:2JC9}.
FT   STRAND      327    329       {ECO:0000244|PDB:2JC9}.
FT   HELIX       332    339       {ECO:0000244|PDB:2JC9}.
FT   HELIX       343    345       {ECO:0000244|PDB:2JC9}.
FT   STRAND      346    351       {ECO:0000244|PDB:2JC9}.
FT   HELIX       353    357       {ECO:0000244|PDB:2JC9}.
FT   HELIX       358    364       {ECO:0000244|PDB:2JC9}.
FT   STRAND      367    371       {ECO:0000244|PDB:2JC9}.
FT   HELIX       375    384       {ECO:0000244|PDB:2JC9}.
FT   HELIX       386    398       {ECO:0000244|PDB:2JC9}.
FT   HELIX       421    432       {ECO:0000244|PDB:2JC9}.
FT   STRAND      440    443       {ECO:0000244|PDB:2JC9}.
FT   HELIX       449    457       {ECO:0000244|PDB:2JC9}.
FT   STRAND      459    463       {ECO:0000244|PDB:2JC9}.
FT   HELIX       465    470       {ECO:0000244|PDB:2JC9}.
FT   HELIX       485    487       {ECO:0000244|PDB:2JC9}.
SQ   SEQUENCE   561 AA;  64970 MW;  4C27D762575E0EA2 CRC64;
     MSTSWSDRLQ NAADMPANMD KHALKKYRRE AYHRVFVNRS LAMEKIKCFG FDMDYTLAVY
     KSPEYESLGF ELTVERLVSI GYPQELLSFA YDSTFPTRGL VFDTLYGNLL KVDAYGNLLV
     CAHGFNFIRG PETREQYPNK FIQRDDTERF YILNTLFNLP ETYLLACLVD FFTNCPRYTS
     CETGFKDGDL FMSYRSMFQD VRDAVDWVHY KGSLKEKTVE NLEKYVVKDG KLPLLLSRMK
     EVGKVFLATN SDYKYTDKIM TYLFDFPHGP KPGSSHRPWQ SYFDLILVDA RKPLFFGEGT
     VLRQVDTKTG KLKIGTYTGP LQHGIVYSGG SSDTICDLLG AKGKDILYIG DHIFGDILKS
     KKRQGWRTFL VIPELAQELH VWTDKSSLFE ELQSLDIFLA ELYKHLDSSS NERPDISSIQ
     RRIKKVTHDM DMCYGMMGSL FRSGSRQTLF ASQVMRYADL YAASFINLLY YPFSYLFRAA
     HVLMPHESTV EHTHVDINEM ESPLATRNRT SVDFKDTDYK RHQLTRSISE IKPPNLFPLA
     PQEITHCHDE DDDEEEEEEE E
//
